AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34516433 — intervention group
Group type: COMPARATOR
Intervention: Usual conservative care
Number of subjects: 38
Study 34051909 — intervention group
Group type: EXPERIMENTAL
Intervention: COACHES in Schools program
Number of subjects: 61
Study 34051909 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 61
Study 34185225 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-item University of Washington concerns about pain (UWCAP)
Number of subjects: 241
Study 34185225 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-item University of Washington pain-related self-efficacy (UWPRSE)
Number of subjects: 241
Study 34185225 — intervention group
Group type: EXPERIMENTAL
Intervention: UWCAP
Number of subjects: 241
Study 34185225 — intervention group
Group type: EXPERIMENTAL
Intervention: Change scores and effect sizes across treatment response categories
Number of subjects: 241
Study 34550930 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial breast augmentation
Number of subjects: 20
Study 34550930 — intervention group
Group type: COMPARATOR
Intervention: Subglandular breast augmentation
Number of subjects: 20
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-mRNA booster vaccination
Number of subjects: 263
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-mRNA primary vaccination
Number of subjects: 263
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-mRNA vaccination in IBD patients treated with TNF-α inhibitors
Number of subjects: 263
Study 35634285 — intervention group
Group type: COMPARATOR
Intervention: Control group (66 patients)
Number of subjects: 263
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: MM patients
Number of subjects: 263
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: SOT patients
Number of subjects: 263
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients
Number of subjects: 263
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: S1-specific IgG levels
Number of subjects: 263
Study 35634285 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19+ B-cell counts
Number of subjects: 263
Study 32592973 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with 60 ml CM and ASIR-V
Number of subjects: 119
Study 32592973 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kVp protocol with 45 ml CM and ASIR-V
Number of subjects: 119
Study 32592973 — intervention group
Group type: COMPARATOR
Intervention: 120-kVp protocol with 60 ml CM and filtered back projection
Number of subjects: 119
Study 36031855 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy delivered using an MP3 player and headphones
Number of subjects: 90
Study 36031855 — intervention group
Group type: COMPARATOR
Intervention: Non-music group (control)
Number of subjects: 90
Study 32096197 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) using CalliSpheres beads loading with arsenic trioxide (CBATO)
Number of subjects: 86
Study 32096197 — intervention group
Group type: COMPARATOR
Intervention: Conventional TACE (cTACE) with arsenic trioxide (ATO)
Number of subjects: 86
Study 37286390 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week standardised exercise program including head lifts, abdominal curl‐ups and twisted abdominal curl‐ups 5 days a week
Number of subjects: 70
Study 37286390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 33539062 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution applied once daily for 18-24 months
Number of subjects: 101
Study 32646282 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational judo training (JT) for 12 weeks, 60-min sessions, 2 times/week at 65-75% maximal heart rate
Number of subjects: 35
Study 35245284 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaNet insecticide-treated window curtains (ITCs)
Number of subjects: 6223
Study 35245284 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent insecticide-treated water storage jar covers (ITJCs)
Number of subjects: 6223
Study 35245284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ITCs and ITJCs
Number of subjects: 6223
Study 35245284 — intervention group
Group type: COMPARATOR
Intervention: No insecticide treated materials (ITMs)
Number of subjects: 6223
Study 35245284 — intervention group
Group type: COMPARATOR
Intervention: External control (15 clusters located at least 5km from the study site)
Number of subjects: 6223
Study 32178608 — intervention group
Group type: EXPERIMENTAL
Intervention: 19,20‐dihydroervahanine A
Number of subjects: 0
Study 32178608 — intervention group
Group type: EXPERIMENTAL
Intervention: 19,20‐dihydrotabernamine
Number of subjects: 0
Study 32178608 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐Clavandurylkaempferol
Number of subjects: 0
Study 32178608 — intervention group
Group type: EXPERIMENTAL
Intervention: Na‐methylepipachysamine D
Number of subjects: 0
Study 32178608 — intervention group
Group type: EXPERIMENTAL
Intervention: ebeiedinone
Number of subjects: 0
Study 32178608 — intervention group
Group type: EXPERIMENTAL
Intervention: dictyophlebine
Number of subjects: 0
Study 33964555 — intervention group
Group type: EXPERIMENTAL
Intervention: Real indoor air filtration
Number of subjects: 57
Study 33964555 — intervention group
Group type: COMPARATOR
Intervention: Sham indoor air filtration
Number of subjects: 57
Study 35405088 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus pertuzumab plus paclitaxel
Number of subjects: 134
Study 35405088 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus pertuzumab
Number of subjects: 134
Study 32699904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoz rituximab (SDZ‐RTX)
Number of subjects: 312
Study 32699904 — intervention group
Group type: COMPARATOR
Intervention: Reference rituximab (Ref‐RTX)
Number of subjects: 312
Study 32122397 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises (PSE) at home
Number of subjects: 150
Study 32122397 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises (PSE) at home with continuous counseling through an app
Number of subjects: 150
Study 32122397 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises (PSE) with face-to-face therapy by a speech and language pathologist
Number of subjects: 150
Study 33729038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) plus 36 sessions of group exercise
Number of subjects: 0
Study 33729038 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33370803 — intervention group
Group type: EXPERIMENTAL
Intervention: aHBP
Number of subjects: 50
Study 33370803 — intervention group
Group type: EXPERIMENTAL
Intervention: vHBP
Number of subjects: 50
Study 35381576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 844
Study 35381576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 844
Study 35381576 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab-chemotherapy
Number of subjects: 844
Study 33711991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) 2 mg/kg, subcutaneous, twice weekly for 6 weeks
Number of subjects: 20
Study 33711991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 20
Study 33711991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 20
Study 35876371 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced stapler (RS)
Number of subjects: 199
Study 35876371 — intervention group
Group type: COMPARATOR
Intervention: Standard stapler (SS)
Number of subjects: 199
Study 35421223 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous WTN (25 dB(A)) throughout the night
Number of subjects: 68
Study 35421223 — intervention group
Group type: EXPERIMENTAL
Intervention: WTN (25 dB(A)) only during periods of established sleep
Number of subjects: 68
Study 35421223 — intervention group
Group type: EXPERIMENTAL
Intervention: WTN (25 dB(A)) only during periods of wake or light N1 sleep
Number of subjects: 68
Study 35421223 — intervention group
Group type: COMPARATOR
Intervention: Quiet control night (19 dB(A) background laboratory noise)
Number of subjects: 68
Study 34398641 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row fixation
Number of subjects: 90
Study 34398641 — intervention group
Group type: COMPARATOR
Intervention: Single-row fixation
Number of subjects: 90
Study 32814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced concentrations of cardiomyocyte PITX2
Number of subjects: 359
Study 32814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated BMP10 plasma concentrations
Number of subjects: 359
Study 32814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial size
Number of subjects: 359
Study 32814717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparoxysmal AF
Number of subjects: 359
Study 32814717 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP10 compared to 11 other cardiovascular biomarkers
Number of subjects: 359
Study 34346910 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-A (aerobic-only high-intensity interval training)
Number of subjects: 58
Study 34346910 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-AR (aerobic/resistance high-intensity interval training)
Number of subjects: 58
Study 34346910 — intervention group
Group type: COMPARATOR
Intervention: CG (resting control group)
Number of subjects: 58
Study 34508594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab monotherapy (200 mg every 2 weeks)
Number of subjects: 583
Study 34508594 — intervention group
Group type: COMPARATOR
Intervention: Sarilumab plus methotrexate
Number of subjects: 583
Study 33735463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking therapy for a minimum of 20 minutes daily
Number of subjects: 152
Study 33735463 — intervention group
Group type: COMPARATOR
Intervention: Control group with same type of chair but without rocking therapy
Number of subjects: 152
Study 36051928 — intervention group
Group type: EXPERIMENTAL
Intervention: DPL combined with clarithromycin
Number of subjects: 86
Study 36051928 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 34897099 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat
Number of subjects: 29
Study 34897099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 32143644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Program (MB) delivered by paraprofessional staff
Number of subjects: 874
Study 32143644 — intervention group
Group type: COMPARATOR
Intervention: Mothers and Babies Program (MB) delivered by mental health professionals
Number of subjects: 874
Study 35436209 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 50
Study 35436209 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 50
Study 33789909 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based approach (FBA)
Number of subjects: 159
Study 33789909 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate counting (CC)
Number of subjects: 159
Study 33789909 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 159
Study 32215726 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato-based products (1.6 g kg-1)
Number of subjects: 16
Study 32215726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport supplements (1.6 g kg-1)
Number of subjects: 16
Study 35332058 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 0
Study 35332058 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg every other week
Number of subjects: 0
Study 35332058 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily (switched from placebo)
Number of subjects: 0
Study 35341943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurcov (three doses on Day 1 as an adjuvant to standard of care)
Number of subjects: 120
Study 35341943 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 120
Study 33764681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted lumbar punctures
Number of subjects: 62
Study 32067585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 53
Study 32067585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 35445819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 15
Study 35445819 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 15
Study 33271975 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention (AMIN)
Number of subjects: 0
Study 35553043 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Events (AEs)
Number of subjects: 450
Study 34644765 — intervention group
Group type: EXPERIMENTAL
Intervention: WALANT
Number of subjects: 78
Study 34644765 — intervention group
Group type: COMPARATOR
Intervention: IVRA
Number of subjects: 78
Study 32349059 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery and again 3 hours later (Group C)
Number of subjects: 150
Study 32349059 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg loading dose intravenous infusion 30 minutes before surgery (Group B)
Number of subjects: 150
Study 32349059 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline solution without TXA (Group A)
Number of subjects: 150
Study 32349059 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (both Group B and Group C)
Number of subjects: 150
Study 34280552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed Fecal Immunochemical Test (FIT) outreach with advanced notification call and informational postcard
Number of subjects: 10771
Study 34280552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed Fecal Immunochemical Test (FIT) outreach
Number of subjects: 10771
Study 34280552 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 10771
Study 34253077 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Therapy (AMP) for alcohol use (AMP‐A) delivered in 11 individual sessions
Number of subjects: 8
Study 34053752 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrumentation (PSI)
Number of subjects: 173
Study 34053752 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 173
Study 32039852 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Physical Exercise Program
Number of subjects: 70
Study 32039852 — intervention group
Group type: COMPARATOR
Intervention: Social Stimulation Program
Number of subjects: 70
Study 34648061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body prehabilitation intervention
Number of subjects: 49
Study 34648061 — intervention group
Group type: COMPARATOR
Intervention: Exercise prehabilitation intervention
Number of subjects: 49
Study 36202588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum-related perinatal mortality among caesarean births
Number of subjects: 5134
Study 36202588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted mortality rates after case mix adjustment
Number of subjects: 5134
Study 36202588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted mortality rates after adjusting for caesarean care components
Number of subjects: 5134
Study 33421309 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin added to teneligliptin (COMB group)
Number of subjects: 99
Study 33421309 — intervention group
Group type: COMPARATOR
Intervention: Teneligliptin switched to canagliflozin (SWITCH group)
Number of subjects: 99
Study 33034628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence visualization-guided surgery
Number of subjects: 443
Study 33034628 — intervention group
Group type: COMPARATOR
Intervention: Non-fluorescence visualization-guided surgery (Control)
Number of subjects: 443
Study 35617945 — intervention group
Group type: EXPERIMENTAL
Intervention: Random‐Errorless group
Number of subjects: 120
Study 35617945 — intervention group
Group type: COMPARATOR
Intervention: Random group
Number of subjects: 120
Study 35617945 — intervention group
Group type: COMPARATOR
Intervention: Random‐Errorful group
Number of subjects: 120
Study 35617945 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless conditions
Number of subjects: 120
Study 35617945 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorful conditions
Number of subjects: 120
Study 33554268 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin ointment
Number of subjects: 20
Study 33554268 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 20
Study 32690164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification education based on health belief model
Number of subjects: 82
Study 35670369 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 48
Study 35670369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 48
Study 35670369 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 48
Study 35670369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33788162 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 1627
Study 33788162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study 36294463 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 20
Study 36294463 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 32540584 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg, 9 mL anaesthetic agents)
Number of subjects: 136
Study 32540584 — intervention group
Group type: COMPARATOR
Intervention: Low-volume corticosteroid injection (1 mL triamcinolone acetonide/40 mg)
Number of subjects: 136
Study 35860380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) via colonoscopy with donor stool, followed by three enemas over 3 days.
Number of subjects: 0
Study 35860380 — intervention group
Group type: COMPARATOR
Intervention: Oral probiotics (control group).
Number of subjects: 0
Study 33570978 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid mobile intervention targeting MVPA and FV
Number of subjects: 204
Study 33570978 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid mobile intervention targeting SED and FAT
Number of subjects: 204
Study 33570978 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid mobile intervention targeting behaviors
Number of subjects: 204
Study 33570978 — intervention group
Group type: EXPERIMENTAL
Intervention: MBC2 trial examining correlations
Number of subjects: 204
Study 32698457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio group (1.5 oz/day or 42 g/day)
Number of subjects: 100
Study 32698457 — intervention group
Group type: COMPARATOR
Intervention: Control group (behavioral weight loss intervention only)
Number of subjects: 100
Study 32698457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio group
Number of subjects: 100
Study 32698457 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 34014615 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning method for RET enumeration
Number of subjects: 40
Study 34014615 — intervention group
Group type: COMPARATOR
Intervention: Manual method (control)
Number of subjects: 40
Study 32597580 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine (200 mg, 2 tablets of 100 mg p.o., once)
Number of subjects: 60
Study 32597580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same administration scheme as phenazopyridine)
Number of subjects: 60
Study 32597580 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Number of subjects: 60
Study 35318234 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation (tVNS) for 20 min/day for 12 weeks
Number of subjects: 156
Study 35318234 — intervention group
Group type: COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (tVNS) with no electric current for 20 min/day for 12 weeks
Number of subjects: 156
Study 35318234 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tVNS
Number of subjects: 156
Study 35318234 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS
Number of subjects: 156
Study 32329767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Naloxone
Number of subjects: 0
Study 32329767 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular Naloxone
Number of subjects: 0
Study 33774878 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33526730 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day (group 1, n=30)
Number of subjects: 60
Study 33526730 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2, n=30)
Number of subjects: 60
Study 35413714 — intervention group
Group type: EXPERIMENTAL
Intervention: A. annua extracts sublingual immunotherapy (SLIT) with pharmacotherapy
Number of subjects: 88
Study 35413714 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic drugs only (Control)
Number of subjects: 88
Study 33641848 — intervention group
Group type: EXPERIMENTAL
Intervention: m-learning intervention
Number of subjects: 190
Study 33641848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no m-learning intervention)
Number of subjects: 190
Study 32059728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise (CARE) program during chemotherapy
Number of subjects: 301
Study 35796876 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-supraglottic swallow
Number of subjects: 20
Study 35796876 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful swallow
Number of subjects: 20
Study 32434467 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation to promote screening, counseling, and MAT
Number of subjects: 125
Study 32434467 — intervention group
Group type: COMPARATOR
Intervention: Control group (6-month delay in intervention)
Number of subjects: 125